Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

v3.24.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
Total
Public Offering
Private Placement
Equity Line Of Credit
Series F Preferred Stock
Series F Preferred Stock
Public Offering
Series E Preferred Stock
Preferred Stock
Preferred Stock
Series F Preferred Stock
Preferred Stock
Series F Preferred Stock
Public Offering
Preferred Stock
Series E Preferred Stock
Common Stock
Common Stock
Public Offering
Common Stock
Private Placement
Common Stock
Equity Line Of Credit
Common Stock
Series F Preferred Stock
Common Stock
Series E Preferred Stock
Additional Paid-In Capital
Additional Paid-In Capital
Public Offering
Additional Paid-In Capital
Private Placement
Additional Paid-In Capital
Equity Line Of Credit
Additional Paid-In Capital
Series F Preferred Stock
Additional Paid-In Capital
Series F Preferred Stock
Public Offering
Additional Paid-In Capital
Series E Preferred Stock
Accumulated Other Comprehensive Loss
Accumulated Deficit
Balance (in shares) at Dec. 31, 2021               7       316,599                            
Balance at Dec. 31, 2021 $ 14,579,048             $ 0       $ 3,166           $ 135,541,662             $ (86,431) $ (120,879,349)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                    
Stock-Based Compensation 462,450                                 462,450                
Issuance of Panoptes Holdback Shares (in shares)                       10,087                            
Issuance of Panoptes Holdback Shares 0                     $ 100           (100)                
Issuance of Stock (in shares)                     1,280   592,392                          
Issuance of Stock   $ 2,462,838         $ 665,191       $ 13   $ 5,924           $ 2,456,914         $ 665,178    
Issuance of shares of common stock from warrant exercises (in shares)                       65,000                            
Issuance of Shares of Common Stock from Warrant Exercises 520,000                     $ 650           519,350                
Conversion of Preferred Stock into Common Stock (in shares)                     (1,280)           160,000                  
Conversion of Preferred Stock into Common Stock             $ 0       $ (13)           $ 1,600             $ (1,587)    
Reclassification of Warrant Liability 3,674,791                                 3,674,791                
Cancellation of Reverse Stock Split Fractional Shares (in shares)                       (2,215)                            
Cancellation of Reverse Stock Split Fractional Shares (15,629)                                 (15,629)                
Issuance of Common Stock from Warrant Inducement, Net of Issuance Costs of $381,360 (in shares)                       654,609                            
Issuance of Common Stock from Warrant Inducement, Net of Issuance Costs of $381,360 2,738,831                     $ 6,546           2,732,285                
Foreign Currency Translation Adjustment (96,310)                                               (96,310)  
Net Loss (13,583,610)                                                 (13,583,610)
Balance at Dec. 31, 2022 11,407,600             $ 0       $ 17,986           146,035,314             (182,741) (134,462,959)
Balance (in shares) at Dec. 31, 2022               7       1,796,472                            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                    
Stock-Based Compensation 754,944                                 754,944                
Issuance of Stock (in shares)                   3,908     2,197,628 52,798 125,000                      
Issuance of Stock   $ 1,018,455 $ 115,715 $ 442,310   $ 1,646,289       $ 39     $ 21,976 $ 528 $ 1,250       $ 996,479 $ 115,187 $ 441,060   $ 1,646,250      
Issuance of Class C and D warrants from Public Offering, Net of Offering Costs of $381,877 2,931,218                                 2,931,218                
Issuance of shares of common stock from warrant exercises (in shares)                       66,400                            
Issuance of Shares of Common Stock from Warrant Exercises 307,079                     $ 664           306,415                
Conversion of Preferred Stock into Common Stock (in shares)                 (3,488)             3,170,592                    
Conversion of Preferred Stock into Common Stock         $ 0       $ (35)             $ 31,706           $ (31,671)        
Issuance of Common Stock from Restricted Stock Awards (in shares)                       296,750                            
Issuance of Common Stock from Restricted Stock Awards 0                     $ 2,968           (2,968)                
Foreign Currency Translation Adjustment (60)                                               (60)  
Net Loss (12,513,896)                                                 (12,513,896)
Balance at Dec. 31, 2023 $ 6,109,654             $ 4       $ 77,078           $ 153,192,228             $ (182,801) $ (146,976,855)
Balance (in shares) at Dec. 31, 2023               427       7,705,640